Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada - A time and motion study

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Shinder, Gayle A ^a   Paradis, Pierre Emmanuel ^b,c   Posman, Marianne ^d   Mishagina, Natalia ^b,e   Guay, Marie Pascale ^d   Linardos, Dina ^d   Batist, Gerald ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b Groupe d'Analyse Ltee   (Canada)

^c AppEco Analytics   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e CIRANO   (Canada)

Author keywords

Cost analysis; FOLFOX bevacizumab; Metastatic colorectal cancer; Patient flow; Time and motion; Work flow; XELOX bevacizumab

Indexed keywords

ARTICLE; CANADA; CANCER CENTER; COLORECTAL TUMOR; FEMALE; HEALTH CARE; HUMAN; MALE; METASTASIS; NONBIOLOGICAL MODEL; PERSONNEL MANAGEMENT; TASK PERFORMANCE; UTILIZATION REVIEW; WORKFLOW;

CANCER CARE FACILITIES; COLORECTAL NEOPLASMS; COMPREHENSIVE HEALTH CARE; FEMALE; HUMANS; MALE; MODELS, ORGANIZATIONAL; PERSONNEL STAFFING AND SCHEDULING; QUEBEC; TIME AND MOTION STUDIES; WORKFLOW;

EID: 84867900499     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-370     Document Type: Article

References (22)

1. Canadian Partnership Against Cancer, The Future of Cancer Control in Canada. A discussion paper on pan-Canadian cancer control priorities for 2012-2017 Toronto, ON: CPAC 2011
2. Estimating the direct costs of bowel cancer services provided by the National Health Service in England. Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, Tappenden J, Int J Technol Assess Health Care 2010 26 4 362 369 10.1017/S0266462310001078 20942988
3. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real world cost effectiveness analysis. Cromwell I, van der Hoek K, Melosky B, Peacock S, J Thorac Oncol 2011 6 12 2097 2103 10.1097/JTO. 0b013e31822f657a 22052223
4. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaulation of national cancer institute of canada clinical trials group, CO.17 Trial. Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group, J Natl Cancer Inst 2009 101 17 1182 1192 10.1093/jnci/djp232 19666851
5. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP, Br J Cancer 2006 94 1122 1129 10.1038/sj.bjc.6603059 16622438
6. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Faroux R, Florentin V, Douillard JY, Oncology 2010 79 174 180 10.1159/000325999 21358204
7. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. Tse VC, Ng WT, Lee V, Lee AWM, Chua DTT, Chau J, McGhee SM, BMC Cancer 2011 11 288 295 10.1186/1471-2407-11-288 21740590
8. Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer. Aitini E, Rossi A, Morselli P, Vivorio B, Bruschi A, Bottura C, Colombo GL, Cancer Management Res 2012 4 99 103
9. Multileaf collimation versus conventional shielding blocks: a time and motion study of beam shaping in radiotherapy. Helyer SJ, Heisig S, Radiother Oncol 1995 37 61 64 10.1016/0167-8140(95)01616-O 8539458
10. Time in motion-Testing efficiency in the dermatology procedure setting. Fisher J, Lotery H, Henderson C, Dermatol Surg 2009 35 437 445 10.1111/j.1524-4725.2009.01076.x 19292835
11. A 36-hospital time and motion study: How do medical-surgical nurses spend their time? Hendrich A, Chow M, Skierczynski BA, Lu Z, The Permanente J 2008 12 3 25 34
12. A cost analysis of colonoscopy using microcosting and time-and-motion techniques. Henry SG, Ness RM, Stiles RA, Shintani AK, Dittus RS, J Gen Intern Med 2007 22 10 1415 1421 10.1007/s11606-007-0281-6 17665271
13. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Meehan KR, Smith RE, Tchekmedyian JK, Clin Drug Invest 2006 26 10 593 601 10.2165/00044011-200626100-00006
14. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Oglesby A, Sherif B, Odom D, Leahy M, Qian Y, Commun Oncol 2009 6 11 494 502 10.1016/S1548-5315(11)70357-6
15. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis. Dranitsaris G, Castel L, Baladi JF, Schulman KA, J Oncol Pharm Practice 2001 7 27 33 10.1191/1078155201jp077oa
16. Measurement of nursing care time of specific interventions on a hematology-oncology unit related to diagnostic categories. Colombo A, Solberg B, Vanderhoeft E, Ramsay G, Schouten HC, Cancer Nurs 2005 28 6 476 480 10.1097/00002820-200511000-00011 16330970
17. Canadian Cancer Society's Steering Committee on Cancer Statistics, Canadian Cancer Statistics 2012 Toronto, ON: Canadian Cancer Society 2012
18. Viewing metastatic colorectal cancer as a curable chronic disease. Chua TC, Liauw W, Chu F, Morris DL, Am J Clin Oncol 2012 35 1 77 80 10.1097/COC.0b013e3181fe4444 22257778
19. Wasserman DW, Bouganim N, Batist G, Ferrario C, Kavan P, Bevacizumab in combination with chemotherapy in metastatic colorectal cancer-The McGill experience Abstract: 3819, ESMO 2010. http://oncologypro.esmo.org/meeting- resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/ bevacizumab-in-combination-with-chemoth-3819.aspx 23168366
20. Quality improvement project to determine outpatient chemotherapy capacity and improve utilization. Gruber M, Smith D, O'Neal C, Hennessy K, Therrien M, J Nurs Care Qual 2008 23 1 75 83 10.1097/01.NCQ.0000303808.93994.59 18281879
21. Improving the efficiency of a chemotherapy day unit: Applying a business approach to oncology. van Lent WAM, Goedbloed N, van Harten WH, Eur J Cancer 2009 45 800 806 10.1016/j.ejca.2008.11.016 19128953
22. Improving wait time for chemotherapy in an outpatient clinc at a comprehensive cancer center. Kallen MA, Terrell JA, Lewis-Patterson P, Hwang JP, J. Oncol Prac 2012 8 10 1 e7